The Pharma Data

JUNE 17, 2022

Sandoz, a global leader in generic and biosimilar medicines, today announced that the European Medicines Agency (EMA) has accepted the application for high concentration formulation 100 mg/mL (HCF) of its biosimilar Hyrimoz ® (adalimumab) for regulatory review. Source link: [link].

Medicine 52

Medicine Generic Pharmaceutical FDA Approval Packaging 52

The Pharma Data

APRIL 4, 2023

The approval includes all indications covered by the reference medicine*: rheumatic diseases, Crohn’s disease, ulcerative colitis, plaque psoriasis, uveitis and hidradenitis suppurativa. The adalimumab reference medicine (Humira ® *) was first approved with an adalimumab concentration of 50 mg/mL.

Medicine 40

Medicine Generic Pharmaceutical FDA Approval Marketing 40

XTalks

AUGUST 2, 2023

With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions. 2) Paxlovid (nirmatrelvir/ritonavir) Paxlovid is a dual-packaged oral medication for the treatment of COVID-19. Total global revenue from Cosentyx was $4.79

Sales 98

Sales Manufacturing FDA Approval Life Science 98